CN100464789C - Digestive tract stent with anti-cancer medicinal particles - Google Patents
Digestive tract stent with anti-cancer medicinal particles Download PDFInfo
- Publication number
- CN100464789C CN100464789C CNB2005101118001A CN200510111800A CN100464789C CN 100464789 C CN100464789 C CN 100464789C CN B2005101118001 A CNB2005101118001 A CN B2005101118001A CN 200510111800 A CN200510111800 A CN 200510111800A CN 100464789 C CN100464789 C CN 100464789C
- Authority
- CN
- China
- Prior art keywords
- silicone rubber
- medicinal particles
- peplos
- cancer medicinal
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Images
Abstract
A scaffold of the granular anticancer medicine for treating the benign or malignant stenosis of esophagus and digestive tract is disclosed, which has 4 structures consisting of scaffold, granular anticancer medicine, selective coated film on the surface of scaffold, and selective external protective layer.
Description
Technical field
What the present invention relates to is the member of a kind of medicine and technical field of medical instruments, specifically, is a kind of alimentary stent of anti-cancer medicinal particles.
Background technology
Digestive tract is good, malignant stricture is common clinically disease.Wherein, the digestive tract malignant stricture that causes by esophagus, stomach, intestinal, malignant biliary tumor etc. digestive tract cancer patient's disease occurred frequently especially.Except surgical resection, radiation and chemotherapy method, interventional therapy means commonly used mainly contain balloon expandable (mainly for benign stricture) and support is inserted.For middle and advanced stage digestive tract cancer patient, it is considerable palliative treatment means that support is inserted, and can effectively improve middle and advanced stage digestive tract cancer patient's quality of life, prolongs life span.But there are 2 deficiencies at least in conventional metals support and overlay film frame: 1. do not possess real local therapeutic effects, only play the effect of appeasing that mechanical support and short-term subtract disease, and powerless to the generation that prevents the restenosis due to the tumor growth; Though overlay film frame can prevent the interior growth of tumor to a certain extent, but still can not prevent the vertical undue growth and the repressive restenosis of tumor.2. metal rack still need cooperate the whole body drug treatment after implanting, but the cancerous tissue blood drug level after the whole body administration is low, is difficult to reach effective treatment concentration; If want to reach therapeutic effect, just must carry out heavy dose of long term administration treatment, but most cancer therapy drug toxic and side effects is very big, organ lesion or the extremely weak middle and advanced stage digestive tract cancer patient of body constitution have appearred for majority, and be worthless.Be head it off, can reach topical treatment, reduce the purpose of toxic and side effects by medicine is carried on the support in every way.
Find by prior art documents, the Chinese patent publication number is CN2638761Y, open day be JIUYUE in 2004 8 days, patent name is: the esophagus drug stent, this patent readme is: " a kind of by carrier implant patient's esophageal tumor narrow section the esophagus drug stent, it by nitinol alloy wire graticule mesh support, coat the medical polymer film of graticule mesh support, being coated in has silicon rubber film and the trocar sheath that medicine oozes out the hole to constitute on the antitumor drug coating on the medical polymer film, the coated coating.Esophagus drug stent after the implantation, it except the performance and function that keep esophageal stents appear, its treatment with suppress the antitumor drug coating and slowly ooze out contact and reach the purpose for the treatment of esophageal tumor with esophageal tumor from oozing out the hole." its weak point is as follows: the one, the be written into amount of medicine in macromolecular material not enough (the too high mechanical performance that will influence film of drug loading); the 2nd, the rate of release of 5-fluorouracil in silicone rubber medicine film is comparatively slow; behind release-controlled film; the release of medicine will be slower, is difficult to reach therapeutic dose; At last, silastic-layer with holes very easily is subjected to breakage as controlled release layer in the support course of conveying, thereby makes release rate of drugs be subjected to influencing largely.
Summary of the invention
The objective of the invention is to overcome deficiency of the prior art, a kind of digestive tract stent with anti-cancer medicinal particles is provided.Make it be used for the treatment of esophagus and other gastral benign and malignant stenosis, not only has the mechanicalness dilating effect, and has a local therapeutic effects, anti-cancer medicinal particles will directly discharge medicine in tumor tissues or other pathological tissues, the digestive tract benign and malignant stenosis is treated, and what permanent solution digestive tract benign and malignant stenosis caused blocks.
The present invention is achieved by the following technical solutions, and the present invention has four kinds of versions.
First kind of version of the present invention, comprising: support and anti-cancer medicinal particles, anti-cancer medicinal particles are directly taken and are invested on the support.
Second kind of version of the present invention, comprising: support, peplos and anti-cancer medicinal particles, peplos wrap at rack surface, and peplos is close to support, and anti-cancer medicinal particles is taken and is invested on the peplos.
The third version of the present invention comprises: support, anti-cancer medicinal particles and protective layer, anti-cancer medicinal particles are directly taken and are invested on the support, and protective layer is arranged on the anti-cancer medicinal particles aspect.
The 4th kind of version of the present invention, comprising: support, peplos, anti-cancer medicinal particles and protective layer, peplos wrap at rack surface; peplos is close to support; anti-cancer medicinal particles is taken and is invested on the peplos, and protective layer is an outermost layer, and protective layer is arranged on the anti-cancer medicinal particles aspect.
In described four kinds of versions, anti-cancer medicinal particles is stated from anti-cancer medicinal particles on peplos or the bare bracket by physics, chemistry or mechanical mode.
Described physics mode is meant: the effect by physical bond is bonding with anti-cancer medicinal particles, weld, be plated on support or the peplos.
Described chemical mode is meant: the effect by chemical bonding is equipped on anti-cancer medicinal particles on support or the peplos.
Described mechanical system is meant: the effect by external force with anti-cancer medicinal particles by binding, be to connect, be fastened on support or peplos.
Described support is any support that is fit to be positioned over the digestive tract tract.
Described peplos, its material are any biocompatible materials, or the biocompatible materials mixture of different materials.
Described peplos especially refers to following any one or multiple material: silicone rubber, politef, polyurethane, polrvinyl chloride, polyethylene, aluminium foil, polypropylene, polystyrene, Merlon, Carmomer, carboxymethyl cellulose, hydroxypropyl cellulose, polyvinyl pyrrolidone, polyvinyl alcohol, ethylene-vinyl acetate copolymer, poloxamer, starch, arabic gum, gelatin, chitosan, alginate.
Described peplos can be monolayer, also can be multilamellar.
Described anti-cancer medicinal particles not only is confined to bar-shapedly or spherical, can be arbitrary shape.
Described anti-cancer medicinal particles covers the zone on support or peplos surface and does not limit, and can be any distribution mode, the total surface area of support or peplos when maximum area can be expansion.
The carrier material of described anti-cancer medicinal particles can be any one Biodegradable material and Nondegradable material.
Described Biodegradable material especially refers to one or more in the following material: the copolymer of polylactic acid, lactic acid and glycolic, polycaprolactone, chitosan, sodium alginate, gelatin, glucosan, polyvidone.
Described Nondegradable material especially refers to one or more the mixture in the following material: silicone rubber, polyurethane, ethylene-vinyl acetate copolymer, Merlon, politef, polrvinyl chloride, polyethylene, polypropylene, polystyrene.
Described anti-cancer medicinal particles also comprises the blocker, porogen and other filler that change the drug release behavior except that carrier material.
Described blocker especially refers to one or more the mixture in the following material: stearic acid, magnesium stearate, calcium stearate, senior stearic acid, high fatty alcohol, tristerin, Lac.
Described porogen especially refers to one or more the mixture in the following material: hypromellose, methylcellulose, Polyethylene Glycol, polyethylene, polyvinyl pyrrolidone, sucrose.
Described other filler is meant other, and all can change the biocompatible substance of medicine release behavior in carrier.
Described anti-cancer medicinal particles can carry any one or a few antitumor drug.
Described antitumor drug especially refers to following a few class: alkylating agent, antimetabolite, antitumor antibiotics class, plant extract, dioxygen piperazidine class, platinum class, antibody curing cancer drug, gene therapy medicament.
Described protective layer is water-solubility membrane or biological degradability film, perhaps for containing the Nondegradable material membrane in hole.
Described water-solubility membrane, its material especially refer to following any one or a few: polyvinyl pyrrolidone, polyvinyl alcohol, Polyethylene Glycol, poloxamer, polyacrylic acid, sodium polyacrylate, carbomer, starch, dextrin, methylcellulose, hydroxyethyl-cellulose, hydroxypropyl cellulose, hypromellose, arabic gum, gelatin, chitosan, sodium alginate, hyaluronic acid, albumin, agar, poly-maltotriose, xanthan gum, guar gum.
Described biological degradability film, its material especially refer to following any one or a few: polylactide and poly-Acetic acid, hydroxy-, bimol. cyclic ester and copolymer thereof, polybutylcyanoacrylate, polycaprolactone, polyanhydride, poloxamer, poe, polyether ester, natural polysaccharide and modified xylanase, oxidized cellulose, Fibrinogen, fibrin, collagen protein, gelatin and Biodegradable hydrogel.
The described Nondegradable material membrane that contains the hole is especially to refer to following any one or a few: silicone rubber, polyurethane, ethylene-vinyl acetate copolymer, Merlon, politef, polrvinyl chloride, polyethylene, polypropylene, polystyrene.
With the anti-cancer medicinal particles is pharmaceutical carrier; the mechanical performance of support and film will can not be affected; and help to control drug loading, dissolution rate and the absorption of medicine; last on the anti-cancer medicinal particles surface coated with the protecting film that does not influence the drug release behavior; can protect anti-cancer medicinal particles to avoid polluting, and implant smoothly.
Support of the present invention can play the effect of mechanical expansion, also the portability anti-cancer medicinal particles; Coating layer, the portability anti-cancer medicinal particles can prevent that also drug solution from oozing out or the intrusion of digestive tract liquid; Protecting film can protect anti-cancer medicinal particles to avoid polluting, and intact implanting.The loss of protective film and the damaged release that can not influence medicine, this is that general release-controlled film, organic short infiltration layer or medicine film layer itself are inaccessible as protecting film institute.The present invention is pharmaceutical carrier with the anti-cancer medicinal particles, can improve drug loading, and the stripping behavior and the permeable membrane that help to improve medicine absorb.The anti-cancer medicinal particles appendix behind implant into body on the support, the digestive tract tumor position and near can carry out targeting, slowly and long-term release, thereby the digestive tract that innocent and malignant tumour and other pathological changes cause is blocked or narrowly effectively treats.
Description of drawings
Fig. 1 is the front schematic view of first kind of version of the present invention.
Fig. 2 is first kind of version schematic cross-section of the present invention.
Fig. 3 is second kind of version front schematic view of the present invention.
Fig. 4 is second kind of version schematic cross-section of the present invention.
Fig. 5 is the third version front schematic view of the present invention.
Fig. 6 is the third version schematic cross-section of the present invention.
Fig. 7 is the 4th a kind of version front schematic view of the present invention.
Fig. 8 is the 4th a kind of version schematic cross-section of the present invention.
Fig. 9 is the front schematic view of another pattern of second kind of version of the present invention.
The specific embodiment
Embodiment 1
As depicted in figs. 1 and 2, the present invention includes: support 1, anti-cancer medicinal particles 3, anti-cancer medicinal particles 3 directly is carried on the support 1.
Described anti-cancer medicinal particles 3 is for implanting dosage form, and the used carrier material is Acetic acid, hydroxy-, bimol. cyclic ester/lactide copolymer, and described cancer therapy drug is a 5-fluorouracil.Anti-cancer medicinal particles 3 lies on the alloy silk of support 1 by sutures.
The prepared support of the present invention, be used for the treatment of narrow that the esophagus malignant tumor causes, not only has the mechanicalness dilating effect, and the medicine that discharges can be directly acted near pathological tissues or its, thereby carry out slowly, long term administration narrow treatment that the esophagus malignant tumor is caused in the part.
As shown in Figure 3 and Figure 4, the present invention includes: support 1, peplos 2 and anti-cancer medicinal particles 3, peplos 2 wrap on support 1 surface, and peplos 2 is close to support 1, and anti-cancer medicinal particles 3 is stated from peplos 2, and protective layer 4 is located on anti-cancer medicinal particles 3 aspects.
Described peplos 2 materials are polyurethane.
Described anti-cancer medicinal particles 3 is a microsphere, and carrier material is a starch, and antitumor drug is a cisplatin.Anti-cancer medicinal particles invests on the peplos 2 by the acrylic compounds pressure-sensitive adhesive.
The prepared support of the present invention, be used for the treatment of narrow that the esophagus malignant tumor causes, not only has the mechanicalness dilating effect, and the medicine that discharges can be directly acted near pathological tissues or its, thereby carry out slowly, long term administration narrow treatment that the esophagus malignant tumor is caused in the part.
As shown in Figure 5 and Figure 6, the present invention includes: support 1, anti-cancer medicinal particles 3, protective layer 4, anti-cancer medicinal particles 3 directly is carried on the support 1.Protective layer 4 is located on anti-cancer medicinal particles 3 aspects.
Described anti-cancer medicinal particles 3 is a nanosphere, and carrier material is an albumin, and antitumor drug is a hydroxy camptothecin.Anti-cancer medicinal particles 3 directly is adhered on 1 on the support by medical adhesive.
Described protective layer 4 is to be the water-solubility membrane polyvinyl pyrrolidone.
The prepared support of the present invention, be used for the treatment of narrow that the malignant biliary tumor causes, not only has the mechanicalness dilating effect, and the medicine that discharges can be directly acted near pathological tissues or its, thereby carry out slowly, long term administration narrow treatment that the malignant biliary tumor is caused in the part.
Embodiment 4
As shown in Figure 7 and Figure 8; the present invention includes: support 1, peplos 2, anti-cancer medicinal particles 3, protective layer 4, peplos 2 wrap on support 1 surface, and peplos 2 is close to support 1; anti-cancer medicinal particles 3 is taken and is invested on the peplos 2, and protective layer 4 is located on anti-cancer medicinal particles 3 aspects.
Described anti-cancer medicinal particles 3 is an implant, and carrier material is a polylactic acid, and anti-cancer medicinal particles 3 is a paclitaxel.Anti-cancer medicinal particles 3 is connected on the peplos 2 by the thermoplastic elastomer pressure-sensitive adhesive.
Described protective layer 4 is the biodegradable film, and material is natural polysaccharide.
The prepared support of the present invention, be used for the treatment of narrow that the esophagus malignant tumor causes, not only has the mechanicalness dilating effect, and the medicine that discharges can be directly acted near pathological tissues or its, thereby carry out slowly, long term administration narrow treatment that the malignant biliary tumor is caused in the part.
As shown in Figure 9, the present invention includes: support 1, anti-cancer medicinal particles 3 and protective layer 4, anti-cancer medicinal particles 3 directly are carried on the support 1, and protective layer 4 is located on anti-cancer medicinal particles 3 aspects.
Described anti-cancer medicinal particles 3 is for implanting dosage form, and carrier material is a silicone rubber, and antitumor drug is a bleomycin.Implant directly plates by electroplate liquid and is connected to the metal surface.
Described protective layer 4 is to be hypromellose.
The prepared support of the present invention, be used for the treatment of narrow that the esophagus malignant tumor causes, not only has the mechanicalness dilating effect, and the medicine that discharges can be directly acted near pathological tissues or its, thereby carry out slowly, long term administration narrow treatment that the esophagus malignant tumor is caused in the part.
Claims (6)
1, a kind of digestive tract stent with anti-cancer medicinal particles, comprise: support (1) and be the anti-cancer medicinal particles (3) of carrier material with polylactic acid or silicone rubber, it is characterized in that anti-cancer medicinal particles (3) is directly taken by physics mode, chemical mode or mechanical system and invested on the support (1);
Perhaps also comprise: silicone rubber peplos (2), silicone rubber peplos (2) wraps on support (1) surface, silicone rubber peplos (2) is close to support (1), is that the anti-cancer medicinal particles (3) of carrier material is taken by physics mode, chemical mode or mechanical system and invested on the silicone rubber peplos (2) with polylactic acid or silicone rubber;
Perhaps also comprise: the protective layer (4) that forms by polyvinylpyrrolidone, polylactide and poly-Acetic acid, hydroxy-, bimol. cyclic ester, be that the anti-cancer medicinal particles (3) of carrier material is directly taken by physics mode, chemical mode or mechanical system and invested on the support (1) with polylactic acid or silicone rubber, it is on anti-cancer medicinal particles (3) aspect of carrier material that the protective layer (4) that is formed by polyvinylpyrrolidone, polylactide and poly-Acetic acid, hydroxy-, bimol. cyclic ester is arranged on polylactic acid or silicone rubber;
Perhaps also comprise: silicone rubber peplos (2) and by polyvinylpyrrolidone; the protective layer (4) that polylactide and poly-Acetic acid, hydroxy-, bimol. cyclic ester form; silicone rubber peplos (2) wraps on support (1) surface; silicone rubber peplos (2) is close to support (1); with polylactic acid or silicone rubber is that the anti-cancer medicinal particles (3) of carrier material passes through physics mode; chemical mode or mechanical system are taken and are invested on the silicone rubber peplos (2); by polyvinylpyrrolidone; the protective layer (4) that polylactide and poly-Acetic acid, hydroxy-, bimol. cyclic ester form is an outermost layer, and being arranged on polylactic acid or silicone rubber is on anti-cancer medicinal particles (3) aspect of carrier material.
2, digestive tract stent with anti-cancer medicinal particles according to claim 1, it is characterized in that, described with polylactic acid or silicone rubber be carrier material anti-cancer medicinal particles (3) by physics mode, chemical mode or mechanical system be stated from silicone rubber peplos (2) or the bare bracket (1).
3, digestive tract stent with anti-cancer medicinal particles according to claim 2, it is characterized in that described physics mode is meant: the effect by physical bond will with polylactic acid or silicone rubber be the anti-cancer medicinal particles (3) of carrier material bonding, weld, be plated on support (1) or the silicone rubber peplos (2); Described chemical mode is meant: the effect by chemical bonding will be that the anti-cancer medicinal particles (3) of carrier material is equipped on support (1) or the silicone rubber peplos (2) with polylactic acid or silicone rubber; Described mechanical system is meant: the effect by external force will with polylactic acid or silicone rubber be the anti-cancer medicinal particles (3) of carrier material by binding, be to connect, be fastened on support (1) or silicone rubber peplos (2).
4, digestive tract stent with anti-cancer medicinal particles according to claim 1 is characterized in that, described silicone rubber peplos (2) is monolayer, or is multilamellar.
5, digestive tract stent with anti-cancer medicinal particles according to claim 1, it is characterized in that, described anti-cancer medicinal particles (3) is except that carrier material, also comprise the blocker, porogen and other filler that change the drug release behavior, described blocker refers to one or more the mixture in the following material: stearic acid, magnesium stearate, calcium stearate, senior stearic acid, high fatty alcohol, tristerin, Lac; Described porogen refers to one or more the mixture in the following material: hypromellose, methylcellulose, Polyethylene Glycol, polyethylene, polyvinyl pyrrolidone, sucrose; Described other filler is meant the biocompatible substance that changes medicine release behavior in carrier.
6, digestive tract stent with anti-cancer medicinal particles according to claim 1, it is characterized in that, described anti-cancer medicinal particles (3) can carry any one or a few antitumor drug, and described antitumor drug refers to following a few class: alkylating agent, antimetabolite, antitumor antibiotics class, plant extract, dioxygen piperazidine class, platinum class, antibody curing cancer drug, gene therapy medicament.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2005101118001A CN100464789C (en) | 2005-12-22 | 2005-12-22 | Digestive tract stent with anti-cancer medicinal particles |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2005101118001A CN100464789C (en) | 2005-12-22 | 2005-12-22 | Digestive tract stent with anti-cancer medicinal particles |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1792380A CN1792380A (en) | 2006-06-28 |
| CN100464789C true CN100464789C (en) | 2009-03-04 |
Family
ID=36804152
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2005101118001A Expired - Fee Related CN100464789C (en) | 2005-12-22 | 2005-12-22 | Digestive tract stent with anti-cancer medicinal particles |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN100464789C (en) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102363052A (en) * | 2011-11-03 | 2012-02-29 | 陆培华 | Drug-eluting stent carrying short-chain ceramide |
| CN102551928B (en) * | 2011-12-21 | 2016-01-06 | 毛宇 | Medical stent in chemotherapy tract |
| CN103330607B (en) * | 2013-06-27 | 2015-07-01 | 河南科技大学 | Self-retracting intraesophageal bracket capable of carrying radiation elements for partial radiotherapy |
| CN103340706B (en) * | 2013-06-27 | 2015-07-01 | 河南科技大学 | Self-stretching intra-esophageal stent capable of carrying local chemotherapy drugs |
| CN106823128A (en) * | 2017-02-15 | 2017-06-13 | 侯桤浡 | The Ventriculo peritoneal shunt pipe for preventing cancer cell from spreading |
| CN108653828A (en) * | 2017-03-29 | 2018-10-16 | 沈阳药科大学 | A kind of antitumor endoluminal stent overlay film and its preparation method and application |
| CN109852574B (en) * | 2017-11-30 | 2021-11-16 | 山西加乐医疗科技有限责任公司 | Cell scaffold and preparation method thereof |
| CN111097094B (en) * | 2019-12-06 | 2022-03-11 | 泰升医疗有限公司 | Micro-catheter for microvascular nerve decompression |
| CN113941036B (en) * | 2019-12-31 | 2022-11-15 | 浦易(上海)生物技术股份有限公司 | Air flue support |
| CN111904674A (en) * | 2020-07-15 | 2020-11-10 | 西安交通大学医学院第一附属医院 | Adjustable esophagus dilator |
| CN113244446B (en) * | 2021-05-17 | 2022-11-11 | 广东省科学院健康医学研究所 | Magnesium alloy composite material and preparation method and application thereof |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1142976A (en) * | 1995-10-10 | 1997-02-19 | 北京医科大学 | Polymeric cationic saccule and support rack |
| US6156331A (en) * | 1996-02-02 | 2000-12-05 | Alza Corporation | Sustained delivery of an active agent using an implantable system |
| CN1367023A (en) * | 2002-03-08 | 2002-09-04 | 清华大学 | Preparation method of biodegradable medicine composite macromolecular scaffold material |
| WO2004026175A1 (en) * | 2002-09-19 | 2004-04-01 | Petrus Besselink | Vascular filter with improved strength and flexibility |
| CN2638761Y (en) * | 2003-08-29 | 2004-09-08 | 王传金 | Esophagus medicine stent |
| CN1539523A (en) * | 2003-10-30 | 2004-10-27 | 武汉理工大学 | Medical metal bracket capable of absorbing magnetic capsule of drug |
| CN1657023A (en) * | 2005-01-31 | 2005-08-24 | 上海市第一人民医院 | Arsenic trioxide control release elution stent |
-
2005
- 2005-12-22 CN CNB2005101118001A patent/CN100464789C/en not_active Expired - Fee Related
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1142976A (en) * | 1995-10-10 | 1997-02-19 | 北京医科大学 | Polymeric cationic saccule and support rack |
| US6156331A (en) * | 1996-02-02 | 2000-12-05 | Alza Corporation | Sustained delivery of an active agent using an implantable system |
| CN1367023A (en) * | 2002-03-08 | 2002-09-04 | 清华大学 | Preparation method of biodegradable medicine composite macromolecular scaffold material |
| WO2004026175A1 (en) * | 2002-09-19 | 2004-04-01 | Petrus Besselink | Vascular filter with improved strength and flexibility |
| CN2638761Y (en) * | 2003-08-29 | 2004-09-08 | 王传金 | Esophagus medicine stent |
| CN1539523A (en) * | 2003-10-30 | 2004-10-27 | 武汉理工大学 | Medical metal bracket capable of absorbing magnetic capsule of drug |
| CN1657023A (en) * | 2005-01-31 | 2005-08-24 | 上海市第一人民医院 | Arsenic trioxide control release elution stent |
Non-Patent Citations (2)
| Title |
|---|
| 医用高分子膜材料. 郭林等.现代化工，第8卷. 1988 |
| 医用高分子膜材料. 郭林等.现代化工，第8卷. 1988 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1792380A (en) | 2006-06-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN100464789C (en) | Digestive tract stent with anti-cancer medicinal particles | |
| US20220054719A1 (en) | Local Drug Delivery Devices and Methods for Treating Cancer | |
| Chao et al. | Biodegradable cisplatin-eluting tracheal stent for malignant airway obstruction: in vivo and in vitro studies | |
| ES2451653T3 (en) | Implantable medical device with surface erosion polyester drug supply coating | |
| US9610427B2 (en) | Narrow profile composition-releasing expandable medical balloon catheter | |
| Samadzadeh et al. | In vitro anticancer efficacy of Metformin-loaded PLGA nanofibers towards the post-surgical therapy of lung cancer | |
| WO2015070814A1 (en) | Drug-eluting balloon and preparation method therefor | |
| JP2021107420A (en) | Implantable drug delivery compositions and methods of use thereof | |
| CN1762330A (en) | Medicine-loading sustained-releasing nanosphere alimentary tract stent | |
| KR102338079B1 (en) | Drug delivery systems and methods for treatment of bladder cancer with gemcitabine | |
| CN106039547A (en) | Expandable devices and methods therefor | |
| Shaikh et al. | Non-vascular drug eluting stents as localized controlled drug delivery platform: preclinical and clinical experience | |
| EP2948198A1 (en) | Trans-arterial drug delivery | |
| US7264822B2 (en) | Conjugated drug-polymer coated stent | |
| CN101559011B (en) | Drug release tubular support provided with internal supporting wings | |
| EP1790335A1 (en) | Composition and its use for the manufacture of a medicament for treating, prophylactically treating, preventing cancer and/or infections in the urinary tract | |
| CN1762331A (en) | Skeleton pattern medicine film encapsulated alimentary tract stent | |
| JP2005527276A (en) | Coated stent with protective assembly and method of use | |
| WO2005058200A1 (en) | Systems for gel-based medical implants | |
| CN114286668A (en) | Local, sustained, controlled release implantable depot of therapeutic agents for treating cancer and related symptoms and conditions | |
| CN1745726A (en) | Alimentary stent with biological degradable medicine slow-releasing membrane coating | |
| CN101959542A (en) | Drug delivery system | |
| Abu Owida et al. | Advancement of nanofibrous mats and common useful drug delivery applications | |
| WO2010072109A1 (en) | A sustained release system for tumor treating medicament | |
| ES2316935T3 (en) | BIOMEDICAL DEVICES WITH POLYMER COATING. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20090304 Termination date: 20161222 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |